Rinvoq ER 15 MG tablet UU 30S
Ended Awarded
- Contract number
- SPE2DB25FWSKM
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,623
Award facts
- Contract value 100% obligated
- $3,622.62 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a Firm Fixed Price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) valued at $3,622.62, with an ultimate completion date of July 30, 2025. This is a non-set-aside, competitively awarded contract executed on July 29, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999.99 million and extends through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with place of performance at its Corporate Office location in Conshohocken.
This delivery order exemplifies AmerisourceBergen's role as a prime vendor within the DLA's pharmaceutical supply chain, fulfilling military and federal healthcare system requirements. RINVOQ (upadacitinib) is a JAK inhibitor used primarily for rheumatoid arthritis treatment and represents the type of specialty pharmaceutical product supplied through the company's comprehensive IDC vehicle. The SPE2DX contract serves as a global pharmaceutical support mechanism enabling AmerisourceBergen to supply an extensive range of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems worldwide.
Quick answers
Who was awarded contract SPE2DB25FWSKM?
SPE2DB25FWSKM was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on July 29, 2025.
How much is contract SPE2DB25FWSKM worth?
The government has obligated $3,623 on SPE2DB25FWSKM.
Is contract SPE2DB25FWSKM an order under another contract?
Yes. SPE2DB25FWSKM is a delivery order under SPE2DB25D3007, an indefinite delivery contract.
Was contract SPE2DB25FWSKM competed?
The extent of competition for SPE2DB25FWSKM was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award